

University of Groningen

## Oncolytic virotherapy - analysis, design, models

Bhatt, Darshak

DOI:  
[10.33612/diss.859671389](https://doi.org/10.33612/diss.859671389)

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*  
Publisher's PDF, also known as Version of record

*Publication date:*  
2024

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Bhatt, D. (2024). *Oncolytic virotherapy - analysis, design, models*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen. <https://doi.org/10.33612/diss.859671389>

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*



# CHAPTER 4

## Tumor-Derived Extracellular Vesicles: Modulation of Cellular Functional Dynamics in Tumor Microenvironment and Its Clinical Implications

---

**Nathalia Leal Santos,<sup>1</sup> Silvina Odete Bustos,<sup>1</sup> Darshak Bhatt,<sup>1,2</sup>  
Roger Chammas,<sup>1\*</sup> Luciana Nogueira de Sousa Andrade<sup>1\*</sup>**

1 Center for Translational Research in Oncology, Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

2 Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, Groningen, Netherlands

\* Corresponding author

Published in Front Cell Dev Biol. 2021

## **Abstract**

Cancer can be described as a dynamic disease formed by malignant and stromal cells. The cellular interaction between these components in the tumor microenvironment (TME) dictates the development of the disease and can be mediated by extracellular vesicles secreted by tumor cells (TEVs). In this review, we summarize emerging findings about how TEVs modify important aspects of the disease like continuous tumor growth, induction of angiogenesis and metastasis establishment. We also discuss how these nanostructures can educate the immune infiltrating cells to generate an immunosuppressive environment that favors tumor progression. Furthermore, we offer our perspective on the path TEVs interfere in cancer treatment response and promote tumor recurrence, highlighting the need to understand the underlying mechanisms controlling TEVs secretion and cargo sorting. In addition, we discuss the clinical potential of TEVs as markers of cell state transitions including the acquisition of a treatment-resistant phenotype, and their potential as therapeutic targets for interventions such as the use of extracellular vesicle (EV) inhibitors to block their pro-tumoral activities. Some of the technical challenges for TEVs research and clinical use are also presented.

**Keywords:** extracellular vesicles, tumor microenvironment, cell communication, tumor progression, functional dynamics

## **Introduction**

Malignant tumors are defined as a microenvironment composed not only by different clones of tumor cells, but also by stromal cells as well as extracellular matrix (ECM).<sup>1</sup> All these components interact with each other dictating the natural history of the disease and the response to treatment. From an ecological point of view, these interactions can be described as cooperative or competitive and, in both cases, depend on the mechanism of cellular communication.<sup>2</sup> In fact, these interactions are dynamic and mediated not only by soluble factors secreted by cells or trapped in the ECM, but also by extracellular vesicles (EVs).<sup>3</sup>

Extracellular vesicles are spherical lipid bilayer structures secreted by many cell types which play an important role in tumor progression.<sup>4</sup> In the last decade, it has become clear that EVs shuttle messages between cells at short and large distances, changing the way cell communication has been described so far.<sup>5</sup> Two major classes of EVs, exosomes (or small vesicles, from 30 to up 150 nm in size) and microvesicles (or large vesicles, from > 100 nm to 1  $\mu$ m) are the most studied and better characterized among the other EVs types. Exosomes have endocytic origin, being formed as intraluminal vesicles (ILVs) by inward budding of the limiting membrane of late endosomes. After the fusion of multivesicular bodies with the plasma membrane, exosomes are released into the extracellular environment. By contrast, microvesicles are formed by outward budding of the plasma membrane.<sup>6</sup> The other classes of EVs, like large oncosomes, apoptotic bodies and platelet-derived vesicles, will not be discussed in this Review.

Amongst the diverse means of communication, EVs are the only ones that are known to carry almost all types of signaling molecules varying from DNA, different types of RNAs, protein/ligands, enzymes, metabolites, growth factors, lipids and even cytokines as recently described.<sup>7-10</sup> In general; EVs exert their effects by the transfer of their cargo to recipient cells modulating their phenotype and function.<sup>11</sup> In this review, we will discuss some examples of how EVs can orchestrate cellular communication in the tumor microenvironment (TME) to promote tumor progression. In addition, we will exploit the role of these EVs in treatment response and discuss the gaps and future directions for clinics and EVs research. We apologize to all authors whose relevant and important work could not be cited due to space constraints.

### *TEVs as Important Mediators of Cell Communication During Malignant Transformation and Tumor Progression*

In the past years, several groups showed that extracellular vesicles secreted by tumor cells (Tumor-Derived Extracellular Vesicles, TEVs) can modulate the cancer hallmarks described in 2011.<sup>12</sup> For example, it is already known that TEVs are able to promote cooperation with stromal cells like endothelial cells to allow tumor development,<sup>13</sup> to suppress the anti-tumor immune response in cancer patients,<sup>14</sup>

and to signal at distant sites to resident cells for the establishment of pre-metastatic niche.<sup>15</sup>

In fact, TEVs can also participate in tumor initiation and propagation. In the study of Kalra et al.,<sup>16</sup> TEVs from colorectal cancer (CRC) cells harboring  $\beta$ -catenin mutation were shown to transfer this protein to wild-type CRC recipient cells, inducing the activation of WNT signaling pathway in these cells and, consequently, boosting tumor growth in xenograft models. Similarly, Fonseka et al. showed that TEVs secreted by N-myc-amplified neuroblastoma cells increased the proliferative and migratory potential of N-myc-non-amplified tumor cells, increasing tumor aggressiveness.<sup>17</sup> Furthermore, very recently, an interesting study conducted by Kilinc et al. demonstrated that oncogene activation led to regulation of EVs release and cargo, suggesting that these nanostructures are biologically relevant even in the initial phases of the disease (Figure 1A).<sup>18</sup>

Beyond this scenario, an important hallmark of solid tumors is the induction of angiogenesis – a sine qua non-condition for continuous tumor growth and progression.<sup>19</sup> More recently, several groups showed that TEVs are one of the mediators for this process.<sup>20-25</sup> Indeed; in 2017, it was demonstrated that TEVs from glioma stem-like cells carried VEGF-A.<sup>26</sup> One year later, Tang et al. observed that TEVs from ovarian cancer contained E-cadherin in their surface which were able to form heterodimers with VE-cadherin in endothelial cells, promoting their sprouting and angiogenesis *in vivo*.<sup>27</sup> Furthermore, Sato et al. demonstrated that higher expression of EPHB2 within EVs isolated from head and neck squamous carcinoma cell lines were able to promote angiogenesis through the activation of ephrin reverse signaling in endothelial cells.<sup>28</sup> Interestingly, Ko et al. observed that TEVs from ovarian cancer induced migration and tube formation by endothelial cells through a bevacizumab-insensitive VEGF presented in vesicles, showing that TEVs can also impair the efficacy of anti-angiogenic therapies.<sup>29</sup> Furthermore, the pro-angiogenic role of TEVs can also be a consequence of their uptake by other stromal cells like fibroblasts, inducing a pro-tumoral phenotype in these cells (Figure 1B).<sup>30,31</sup>




Figure 1: Tumor-derived extracellular vesicles (TEVs) as mediators of tumor development and their use as potential theranostic biomarkers in oncology. (A) TEVs have been recognized as important modulators of many biological processes that govern tumor initiation such as sustained cell growth, evasion of antiproliferative and death stimuli, and immune evasion. Their uptake by tumor and stromal cells induces phenotype

reprogramming that supports malignant transformation and tumor establishment. (B) Along tumor progression these nanostructures are able to create a permissive microenvironment characterized by sustained angiogenesis, inflammatory and immunosuppressive milieu at short and long distances supporting the formation of the pre-metastatic niche (PNM). (C) In addition, TEVs secreted in response to therapy can elicit a bystander effect in both tumor and stromal cells, inducing cell survival and outgrowth resulting in tumor recurrence. (D) In the clinical setting, since TEVs can reach all body fluids, they can be found in peripheral circulation and used for cancer diagnosis, prognosis and also as biomarkers for monitoring tumor response to therapies. Figure created using Biorender.

Additionally, environmental stimuli like hypoxia can somehow modify TEVs release and/or TEVs cargo leading to increased angiogenesis.<sup>32-36</sup> Under hypoxia, for example, lung cancer cells produce more exosomes in comparison to normoxia. Elevated levels of miR-23a were found inside these exosomes which targeted prolyl hydroxylase 1 and 2 (PHD1 and 2), leading to an increase in HIF-1 alpha in endothelial recipient cells and sustained angiogenesis and tumor growth in vivo. Furthermore, enrichment of Wnt4 protein and carbonic anhydrase 9 (CA9) in TEVs in response to hypoxia were demonstrated to be responsible for increased angiogenesis in colorectal cancer.<sup>37,38</sup> Beyond angiogenesis, TEVs secreted under hypoxia can also promote cancer progression through the induction of drug resistance,<sup>39</sup> stemness phenotype and increased invasive capability.<sup>40</sup>

In fact, concerning metastasis, the mechanisms triggered by TEVs are quite diverse. EVs derived from the plasma of CRC patients were enriched with ITGBL1 and associated with lung and liver metastasis. This effect was caused by the activation of resident fibroblasts, which were induced to secrete pro-inflammatory cytokines, promoting the establishment of the pre-metastatic niche.<sup>41</sup> Similarly, EVs secreted by pancreatic tumor cells were shown to be selectively taken up by Kupffer cells (KC) in the liver leading to the release of TGF $\beta$  and the production of fibronectin by hepatic stellate cells, which recruited bone marrow-derived macrophages to establish a pro-inflammatory milieu to facilitate tumor metastasis.<sup>15</sup> Few years later, Zeng et al. observed that TEVs from CRC not only increased vascular permeability, but also enhanced CRC metastasis in liver and lungs.<sup>42</sup> Moreover, exosomes carrying miR-122 released by breast cancer cells reduced glucose uptake by normal recipient cells in pre-metastatic niche, increasing nutrient supply for metastatic cells.<sup>43</sup> Then, the metastatic effect by



TEVs can also be mediated by their effect in stromal cells like fibroblasts;<sup>44,45</sup> macrophages<sup>46,47</sup> and in bone stroma<sup>48</sup> at long distances (Figure 1B).

### *The Establishment of an Immunosuppressive Environment by TEVs*

Regarding the regulation of immune cells in TME, TEVs can educate infiltrating immune cells to cooperate with malignant cells, creating a permissive environment for tumor progression. In this context, EVs shed by GBM cells displaying PD-L1 were able to induce CD8 T cells exhaustion by directly binding to PD-1, thus facilitating tumor progression and impairing immunotherapy treatment efficacy.<sup>49</sup> Similar results were obtained for EVs derived from metastatic melanoma.<sup>50</sup> In NSCLC patients, PD-L1 enriched exosomes from these patients inhibited IL-2 and IFN- $\gamma$  production by T CD8+ lymphocytes.<sup>51</sup> In fact, exosomal PD-L1 is already pointed out as an important biomarker in treatment management which demonstrates the translation of these findings into clinical practice. In hepatocarcinoma cells, TEVs can induce an immunosuppressive phenotype also in infiltrating B cells.<sup>52</sup> In addition, interestingly, these immunosuppressive effects of TEVs also occur at long distances beyond the primary tumor site. Hsieh et al. showed that EVs shed by head and neck cancer cells induced M2 polarization through the transfer of miR-21 to CD14+ human monocytes, favoring tumor growth (Figure 1B).<sup>53</sup> In fact, this work shows that these cooperative relationships mediated by TEVs are not restricted to the tumor primary site and indeed can be established even at larger distances due to their presence in all body fluids, reinforcing the notion of cancer as a systemic disease under the influence of vesicles.

### *Treatment-Elicited TEVs Promotes Tumor Re-Growth*

Tumor recurrence is considered one of the major causes of treatment failure, being directly correlated with a poor prognosis. The cellular mechanisms behind this involve intrinsic and/or acquired resistance.<sup>54</sup> The latter one can be mediated by vesicular cargo transfer of multidrug resistance transporters,<sup>55,56</sup> anti-apoptotic and pro-tumorigenic molecules from resistant to sensitive tumor cells.<sup>57,58</sup> For example, Mrowczynski et al. showed that EVs derived from nervous system cancer cells upon Ionizing Radiation (IR) therapy could induce cell death evasion and

consequent treatment resistance.<sup>59</sup> Interestingly, higher radiation doses were significantly correlated with more expressive decrease in tumor suppressive molecules (STAT4, TPM1, miR-516, and miR-365) and greater increase of oncogenic cargo (CCND1, ANXA2, NPM1, and miR-889). Also, vesicles derived from dying pancreatic cancer cells after radiotherapy were shown to be enriched with miR-194-5p and could potentiate the survival of recipient cells by up-regulating DNA damage responses. In addition, the inhibition of TEVs release by aspirin significantly suppressed tumor re-growth and increased the survival of tumor-bearing mice.<sup>60</sup>

Moreover, EVs released upon chemotherapy have also been reported to promote tumor resistance. Survivin was found to be enriched in EVs secreted by chemotherapy-treated breast cancer cells and was able to promote the survival of tumor cells and tumor associated fibroblasts exposed to paclitaxel.<sup>61</sup> Furthermore, targeted therapy treatment with vemurafenib in BRAF-mutated melanoma cells resulted in altered miRNA and protein profile within EVs, inducing increased resistance in recipient cells.<sup>62</sup> In accordance with these findings, Marconi et al. demonstrated that TEVs secreted by ERBB2 + breast cancer cells in response to trastuzumab carry a different protein cargo that are known to be associated with cytokinesis, lipid metabolism and organelle organization, indicating that this process might be altered in the recipient cells.<sup>63</sup>




Figure 2: Schematic representation of TEVs in cancer biology. Upper corner: pro-tumorigenic effect of TEVs in tumor initiation and progression. Right corner: establishment of an immunosuppressive environment by TEVs. Lower corner: effect of TEVs in pre-metastatic niche formation and in tumor repopulation after therapy. Left corner: the use of TEVs as theranostic biomarkers in oncology. Some of the published articles illustrating these main findings of TEVs were cited in the figure. Figure created using Biorender.

Our group recently demonstrated that EVs release by melanoma cells treated with temozolomide are taken up not only by tumor cells, which showed an increase in pluripotent and DNA repair gene expression levels, but were also able to induce a M2-phenotype in macrophages, promoting tumor repopulation in nude mice.<sup>64</sup> Additionally, EVs released by breast cancer cells upon paclitaxel or doxorubicin treatment were reported to contain higher amounts of ANXA6 protein, which could induce the pre-metastatic niche formation, by promoting Ccl2 expression, monocyte expansion and NF- $\kappa$ B-dependent endothelial cells activation in pulmonary tissues, favoring lung metastasis at in vivo models.<sup>65</sup> In myelomas,

TEVs released upon chemotherapy were able to induce ECM remodeling and promote chemoresistance and relapse (Figure 1C).<sup>66</sup>

Still under this context, another process which is often sped up and induced by cytotoxic therapy is the autophagic flux. In the last few years, some studies have shown cross-regulation between autophagy and exosome release. Initially, autophagy was known as a catabolic process of intracellular degradation of proteins and organelles destined to the recycling of material and the balance of energetic cellular metabolism maintaining cellular homeostasis. However, autophagy can also interfere within the TME communication through its secretory function called secretory autophagy (SA) in a similar way as observed for TEVs.<sup>67-69</sup> Based on studies showing the similarities between EVs and autophagy concerning their biogenesis and secretory function,<sup>70-72</sup> one might speculate that this interconnection can be used by tumor cells to establish a cooperative relationship among different cells in the TME, impacting both tumor progression and treatment response in some tumors as discussed below.

Few years ago, Dutta et al. observed that exosomes released by breast cancer cells were taken up by normal epithelial cells, which was accompanied by an increase in ROS levels and autophagy in recipient cells.<sup>73</sup> Consequently, these cells secreted soluble growth factors that induced the proliferation of malignant cells. More recently, cooperation among different cells in TME was shown to be dependent on the synergism between these two secretory pathways. In response to oxidative stress, pancreatic ductal adenocarcinoma cells released exosomes enriched in KRASG12D during autophagy-dependent ferroptosis. These vesicles were engulfed by macrophages which, in turn, were polarized to M2 phenotype and promoted tumor growth in a mouse model.<sup>74</sup>

About tumor response to therapy, it has been demonstrated that the use of chemotherapy and inhibitors of mTOR pathway led to an increased autophagic flux and, simultaneously, the exosome release.<sup>75-77</sup> Exosomes harvested from irradiated brain cells carrying the miR-7 induced autophagy and transferred this signal to non-irradiated lung cells, mediating a bystander effect of autophagy in the lung after brain irradiation.<sup>78</sup> In non-small cell lung carcinoma cells, exosomal miR-425-3p released in response to cisplatin decreased responsiveness to this drug via targeting the AKT1/mTOR signaling pathway and upregulation of

autophagic activity in recipient cells. On the other hand, enhanced miR-567 levels in HER2 + breast cancer cells were packaged into exosomes which were responsible for suppressing autophagy and reversing chemoresistance by targeting ATG5 in recipient cells.<sup>79</sup>

### *TEVs: From the Bench to the Bedside*

As already discussed, TEVs are multifaceted regulators of tumor progression and response to different therapeutic modalities. Although some aspects regarding their biogenesis and cargo sorting are still largely unknown, their diagnostic and therapeutic potential in oncology have been explored with enthusiasm for several groups. At some level, TEVs cargo reflects the molecular composition of malignant cells and, since these nanostructures can be found in all body fluids, they can serve as circulating biomarkers in liquid biopsy.<sup>80</sup> Moreover, many studies demonstrated that the level of EVs in plasma is significantly higher in cancer patients than healthy individuals as reported for esophageal squamous cell carcinoma<sup>81</sup> and glioblastoma,<sup>82</sup> indicating that EVs plasma quantification can be a useful surrogate indicator for cancer screening. Besides that, it has been demonstrated that plasma exosomal level increases with tumor stage progression as observed in patients with non-small cell lung cancer and can be used also as an indicator of disease progression (Figure 1D).<sup>83</sup>

Another aspect of EVs biology that has been explored in translational studies relies on the presence of macromolecules carried by these nanostructures. A very recent study by Hoshino et al. identified tissue-specific and tumor derived proteins in TEVs from cancer plasma patients in comparison to health individuals, indicating the potential use of vesicular proteins in cancer diagnosis.<sup>84</sup> Moreover, in colorectal patients (CRC), it was found that elevated levels of serum exosomal circ-PNN, a circular RNA, can be used for CRC diagnosis according to the validation analysis conducted by the authors.<sup>85</sup> Interestingly, even the lipidic profile of plasma exosomes shows to be a promising biomarker in cancer.<sup>86</sup> To date, there are 16 clinical studies registered in *Clinicaltrials.gov* that aim to evaluate EVs potential in cancer diagnosis for different tumors, demonstrating that although the biology behind these nanostructures is still largely unknown, their use in clinical practice has been already explored.

Another promising use of TEVs in clinical settings is the potential of EVs as vehicles for the delivery of therapeutic agents which has also generated considerable excitement in the field. In fact, several studies evaluating the use of exosomes for the delivery of miRNAs, mRNAs, proteins, peptides, and synthetic drugs have been performed in the last years.<sup>87,88</sup> Drugs such as doxorubicin,<sup>89</sup> paclitaxel,<sup>90</sup> and siRNA against oncogenic KRASG12D<sup>91</sup> were successfully loaded in EVs and demonstrated potential anticancer effects in vitro and in vivo.

On the other hand, one alternative to explore the use of TEVs in cancer therapy is to reduce the exosome production or inhibit their secretion by tumor cells.<sup>92</sup> A plenty of exosome inhibitors have been discovered and tested in vitro and in pre-clinical models to evaluate their effectiveness against transformed cells especially as neoadjuvant compounds. Most of them were developed to target important molecules of the exosome biogenesis machinery such as Rab27A and sphingomyelinases showing exciting results.<sup>93</sup>

### **Outstanding Questions, Gaps, and Conclusion**

Although remarkable progress has been made in the EVs field, as summarized in Figure 2, there are some gaps in our understanding of molecular mechanisms that control vesicle packaging and also how the cargo loading can be modified in response to different stimuli such as cancer therapies. This aspect is crucial for the comprehension of how EVs can promote resistance and tumor recurrence after therapy and to design new therapeutic strategies to minimize and block these pro-tumoral effects. Furthermore, EVs heterogeneity should be considered in pre-clinical and clinical studies and our understanding of functional differences among EVs classes is still limited. The answer for this question in particular will be necessary especially for the use of EVs as biomarkers in cancer diagnosis and prognosis.

Second, technical challenges are still debated in the EVs community and an effort for the standardization of methods for EV isolation, purification, quantification, and molecular characterization has been made to allow interlaboratory comparisons of pre-clinical and clinical data.

Third, even though interventions in TEVs like the ones involving drug loading and the use of EVs secretion inhibitors indicate therapeutic potential, new criteria become relevant to be investigated such as the timing of therapy, tumors to be treated and chemo-radio-immunotherapy combinations. It is also crucial to determine how the effect of different strategies to regulate exosomes in particular could influence the autophagy machinery or vice versa. Nevertheless, beyond these considerations, we believe that the study of the complex regulation between both pathways after chemo and radiotherapy, among other modalities, may open avenues for the design of novel therapies as well as improve the current ones, avoiding tumor recurrence. Then, in our opinion, the comprehension of the tumor-driven cooperation mediated by TEVs during tumor progression and upon therapy will pave the way to improve therapy outcomes in cancer patients.

### **Author Contributions**

RC and LA conceptualized the manuscript, reviewed, and edited the manuscript before submission. LA, NS, SB, DB, and RC provided intellectual input, analyzed the literature, and participated in the writing. NS prepared the figures. All authors read and approved the final version of the manuscript.

### **Funding**

This research was supported by grants from FAPESP (Grant Number 2020/09176-8 and 2019/07278-0) and CNPq (Grant Number 305700/2017-0). The funder did not play any role in design, interpretation, or writing of the review.

### **Conflict of Interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## References

1. Quail, D. F. & And Joyce, J. A. Microenvironmental Regulation Of Tumor Progression And Metastasis. *Nat. Med* **19**, 1423–1437 (2013).
2. Pelham, C. J., Nagane, M. & And Madan, E. Cell Competition In Tumor Evolution And Heterogeneity: Merging Past And Present. *Semin. Cancer Biol* **63**, 11–18 (2020).
3. Tkach, M. & And Théry, C. Communication By Extracellular Vesicles: Where We Are And Where We Need To Go. *Cell* **164**, 1226–1232 (2016).
4. Schubert, A. & And Boutros, M. Extracellular Vesicles And Oncogenic Signaling. *Mol. Oncol* **15**, 3–26 (2021).
5. Raposo, G. & And Stahl, P. D. Extracellular Vesicles: A New Communication Paradigm? *Nat. Rev. Mol. Cell Biol* **20**, 509–510 (2019).
6. Niel, G., D'angelo, G. & And Raposo, G. Shedding Light On The Cell Biology Of Extracellular Vesicles. *Nat. Rev. Mol. Cell Biol* **19**, 213–228 (2018).
7. Fitzgerald, W. *et al.* A System Of Cytokines Encapsulated In Extracellular Vesicles. *Sci. Rep* **8**, (2018).
8. Anand, S., Samuel, M., Kumar, S. & And Mathivanan, S. Ticket To A Bubble Ride: Cargo Sorting Into Exosomes And Extracellular Vesicles. *Biochim. Biophys. Acta Proteins Proteom* **1867**, (2019).
9. Lázaro-Ibáñez, E. *et al.* Dna Analysis Of Low- And High-Density Fractions Defines Heterogeneous Subpopulations Of Small Extracellular Vesicles Based On Their Dna Cargo And Topology. *J. Extracell. Vesicles* **8**, (2019).
10. O'Brien, K., Breyne, K., Ughetto, S., Laurent, L. C. & And Breakefield, X. O. Rna Delivery By Extracellular Vesicles In Mammalian Cells And Its Applications. *Nat. Rev. Mol. Cell Biol* **21**, 585–606 (2020).
11. Yáñez-Mó, M. *et al.* Biological Properties Of Extracellular Vesicles And Their Physiological Functions. *J. Extracell Vesicles* **4**, (2015).
12. Hanahan, D. & And Weinberg, R. A. Hallmarks Of Cancer: The Next Generation. *Cell* **144**, 646–674 (2011).
13. Aslan, C. *et al.* Tumor-Derived Exosomes: Implication In Angiogenesis And Antiangiogenesis Cancer Therapy. *J. Cell Physiol* **234**, 16885–16903 (2019).
14. Sharma, P., Diergaarde, B., Ferrone, S., Kirkwood, J. M. & And Whiteside, T. L. Melanoma Cell-Derived Exosomes In Plasma Of Melanoma Patients Suppress Functions Of Immune Effector Cells. *Sci. Rep* **10**, (2020).
15. Costa-Silva, B. *et al.* Pancreatic Cancer Exosomes Initiate Pre-Metastatic Niche Formation In The Liver. *Nat. Cell Biol* **17**, 816–826 (2015).
16. Kalra, H. *et al.* Extracellular Vesicles Containing Oncogenic Mutant B-Catenin Activate Wnt Signalling Pathway In The Recipient Cells. *J. Extracell. Vesicles* **8**, (2019).
17. Fonseka, P. *et al.* Exosomes From N-Myc Amplified Neuroblastoma Cells Induce Migration And Confer Chemoresistance To Non-N-Myc Amplified Cells: Implications Of Intra-Tumour Heterogeneity. *J. Extracell. Vesicles* **8**, (2019).
18. Kilinc, S. *et al.* Oncogene-Regulated Release Of Extracellular Vesicles. *Dev. Cell* **2021**, (2021).
19. Folkman, J. Tumor Angiogenesis: A Possible Control Point In Tumor Growth. *Ann. Intern. Med* **82**, 96–100 (1975).
20. Yang, H. *et al.* Exosome-Derived Mir-130a Activates Angiogenesis In Gastric Cancer By Targeting C-Myb In Vascular Endothelial Cells. *Mol. Ther* **26**, 2466–2475 (2018).
21. Bai, M. *et al.* Mir-135b Delivered By Gastric Tumor Exosomes Inhibits Foxo1 Expression In Endothelial Cells And Promotes Angiogenesis. *Mol. Ther* **27**, 1772–1783 (2019).
22. He, L. *et al.* Ovarian Cancer Cell-Secreted Exosomal Mir-205 Promotes Metastasis By Inducing Angiogenesis. *Theranostics* **9**, 8206–8220 (2019).
23. Wang, J. *et al.* Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression: MM exosomes enhance angiogenesis and immunosuppression. *The Journal of Pathology* **239**, 162–173 (2016).



24. Shang, D. *et al.* Pancreatic Cancer Cell-Derived Exosomal MicroRNA-27a Promotes Angiogenesis Of Human Microvascular Endothelial Cells In Pancreatic Cancer Via Btg2. *J. Cell Mol. Med* **24**, 588–604 (2020).
25. Biagioni, A. *et al.* Upar-Expressing Melanoma Exosomes Promote Angiogenesis By Ve-Cadherin, Egfr And Upar Overexpression And Rise Of Erk1,2 Signaling In Endothelial Cells. *Cell Mol. Life Sci* **78**, 3057–3072 (2021).
26. Treps, L., Perret, R., Edmond, S., Ricard, D. & And Gavard, J. Glioblastoma Stem-Like Cells Secrete The Pro-Angiogenic Vegf-A Factor In Extracellular Vesicles. *J. Extracell. Vesicles* **6**, (2017).
27. Tang, M. K. S. *et al.* Soluble E-Cadherin Promotes Tumor Angiogenesis And Localizes To Exosome Surface. *Nat. Commun* **9**, (2018).
28. Sato, S. *et al.* Ephb2 Carried On Small Extracellular Vesicles Induces Tumor Angiogenesis Via Activation Of Ephrin Reverse Signaling. *Jci Insight* **4**, (2019).
29. Ko, S. Y. *et al.* Cancer-Derived Small Extracellular Vesicles Promote Angiogenesis By Heparin-Bound, Bevacizumab-Insensitive Vegf, Independent Of Vesicle Uptake. *Commun. Biol* **2**, (2019).
30. Zhou, X. *et al.* Melanoma Cell-Secreted Exosomal Mir-155-5p Induce Proangiogenic Switch Of Cancer-Associated Fibroblasts Via Socs1/Jak2/Stat3 Signaling Pathway. *J. Exp. Clin. Cancer Res* **37**, (2018).
31. Fan, J., Xu, G., Chang, Z., Zhu, L. & And Yao, J. Mir-210 Transferred By Lung Cancer Cell-Derived Exosomes May Act As Proangiogenic Factor In Cancer-Associated Fibroblasts By Modulating Jak2/Stat3 Pathway. *Clin. Sci* **134**, 807–825 (2020).
32. Chen, X., Zhou, J., Li, X., Wang, X. & And Lin, Y. Exosomes Derived From Hypoxic Epithelial Ovarian Cancer Cells Deliver MicroRNAs To Macrophages And Elicit A Tumor-Promoted Phenotype. *Cancer Lett* **435**, 80–91 (2018).
33. Guo, X. *et al.* Immunosuppressive Effects Of Hypoxia-Induced Glioma Exosomes Through Myeloid-Derived Suppressor Cells Via The Mir-10a/Rora And Mir-21/Pten Pathways. *Oncogene* **37**, 4239–4259 (2018).
34. Wang, X. *et al.* Hypoxic Tumor-Derived Exosomal Mir-301a Mediates M2 Macrophage Polarization Via Pten/Pi3ky To Promote Pancreatic Cancer Metastasis. *Cancer Res* **78**, 4586–4598 (2018).
35. Park, J. E. *et al.* Hypoxia-Induced Tumor Exosomes Promote M2-Like Macrophage Polarization Of Infiltrating Myeloid Cells And MicroRNA-Mediated Metabolic Shift. *Oncogene* **38**, 5158–5173 (2019).
36. Qian, M. *et al.* Hypoxic Glioma-Derived Exosomes Deliver MicroRNA-1246 To Induce M2 Macrophage Polarization By Targeting Terf2ip Via The Stat3 And Nf-Kb Pathways. *Oncogene* **39**, 428–442 (2020).
37. Horie, K. *et al.* Exosomes Expressing Carbonic Anhydrase 9 Promote Angiogenesis. *Biochem. Biophys. Res. Commun* **492**, 356–361 (2017).
38. Huang, Z. & And Feng, Y. Exosomes Derived From Hypoxic Colorectal Cancer Cells Promote Angiogenesis Through Wnt4-Induced B-Catenin Signaling In Endothelial Cells. *Oncol. Res* 651–661 (2017) doi:10.3727/096504016x14752792816791.
39. Dorayappan, K. D. P. *et al.* Hypoxia-Induced Exosomes Contribute To A More Aggressive And Chemoresistant Ovarian Cancer Phenotype: A Novel Mechanism Linking Stat3/Rab Proteins. *Oncogene* **37**, 3806–3821 (2018).
40. Ramteke, A. *et al.* Exosomes Secreted Under Hypoxia Enhance Invasiveness And Stemness Of Prostate Cancer Cells By Targeting Adherens Junction Molecules. *Mol. Carcinog* **54**, 554–565 (2015).
41. Ji, Q. *et al.* Primary Tumors Release Itgbl1-Rich Extracellular Vesicles To Promote Distal Metastatic Tumor Growth Through Fibroblast-Niche Formation. *Nat. Commun* **11**, (2020).
42. Zeng, Z. *et al.* Cancer-Derived Exosomal Mir-25-3p Promotes Pre-Metastatic Niche Formation By Inducing Vascular Permeability And Angiogenesis. *Nat. Commun* **9**, (2018).
43. Fong, M. Y. *et al.* Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. *Nature Cell Biology* **17**, 183–194 (2015).

44. Fang, T. *et al.* Tumor-Derived Exosomal Mir-1247-3p Induces Cancer-Associated Fibroblast Activation To Foster Lung Metastasis Of Liver Cancer. *Nat. Commun* **9**, (2018).
45. Xu, Z., Zheng, X. & And Zheng, J. Tumor-Derived Exosomes Educate Fibroblasts To Promote Salivary Adenoid Cystic Carcinoma Metastasis Via Ngf-Ntrk1 Pathway. *Oncol. Lett* **18**, 4082–4091 (2019).
46. Liang, Z. X. *et al.* Lncrna Rpph1 Promotes Colorectal Cancer Metastasis By Interacting With Tubb3 And By Promoting Exosomes-Mediated Macrophage M2 Polarization. *Cell Death Dis* **10**, (2019).
47. Zhao, S. *et al.* Tumor-Derived Exosomal Mir-934 Induces Macrophage M2 Polarization To Promote Liver Metastasis Of Colorectal Cancer. *J. Hematol. Oncol* **13**, (2020).
48. Dai, J. *et al.* Primary Prostate Cancer Educates Bone Stroma Through Exosomal Pyruvate Kinase M2 To Promote Bone Metastasis. *J. Exp. Med* **216**, 2883–2899 (2019).
49. Ricklefs, F. L. *et al.* Immune Evasion Mediated By Pd-L1 On Glioblastoma-Derived Extracellular Vesicles. *Sci. Adv* **4: Eaar2766**, (2018).
50. Chen, G. *et al.* Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. *Nature* **560**, 382–386 (2018).
51. Kim, D. H. *et al.* Exosomal Pd-L1 Promotes Tumor Growth Through Immune Escape In Non-Small Cell Lung Cancer. *Exp. Mol. Med* **51**, 1–13 (2019).
52. Ye, L. *et al.* Tumor-Derived Exosomal Hmgb1 Fosters Hepatocellular Carcinoma Immune Evasion By Promoting Tim-1. *J. Immunother. Cancer* **6**, (2018).
53. Hsieh, C. H., Tai, S. K. & And Yang, M. H. Snail-Overexpressing Cancer Cells Promote M2-Like Polarization Of Tumor-Associated Macrophages By Delivering Mir-21-Abundant Exosomes. *Neoplasia* **20**, 775–788 (2018).
54. Zhu, X., Li, S., Xu, B. & And Luo, H. Cancer Evolution: A Means By Which Tumors Evade Treatment. *Biomed. Pharmacother* **133**, (2021).
55. Bebawy, M. *et al.* Membrane Microparticles Mediate Transfer Of P-Glycoprotein To Drug Sensitive Cancer Cells. *Leukemia* **23**, 1643–1649 (2009).
56. Corcoran, C. *et al.* Docetaxel-Resistance In Prostate Cancer: Evaluating Associated Phenotypic Changes And Potential For Resistance Transfer Via Exosomes. *Plos One* **7: E50999**, (2012).
57. Khan, S. *et al.* Plasma-Derived Exosomal Survivin, A Plausible Biomarker For Early Detection Of Prostate Cancer. *Plos One* **7: E46737**, (2012).
58. Vella, L. J. *et al.* Intercellular Resistance To Braf Inhibition Can Be Mediated By Extracellular Vesicle-Associated Pdgfrβ. *Neoplasia* **19**, 932–940 (2017).
59. Mrowczynski, O. D. *et al.* Exosomes Impact Survival To Radiation Exposure In Cell Line Models Of Nervous System Cancer. *Oncotarget* **9**, 36083–36101 (2018).
60. Jiang, M. J. *et al.* Dying Tumor Cell-Derived Exosomal Mir-194-5p Potentiates Survival And Repopulation Of Tumor Repopulating Cells Upon Radiotherapy In Pancreatic Cancer. *Mol. Cancer* **19**, (2020).
61. Kreger, B. T., Johansen, E. R., Cerione, R. A. & And Antonyak, M. A. The Enrichment Of Survivin In Exosomes From Breast Cancer Cells Treated With Paclitaxel Promotes Cell Survival And Chemoresistance. *Cancers* **2016**, (2016).
62. Lunavat, T. R. *et al.* Braf(V600) Inhibition Alters The Microrna Cargo In The Vesicular Secretome Of Malignant Melanoma Cells. *Proc. Natl. Acad. Sci. U S A* **114**, 5930–5939 (2017).
63. Marconi, S. *et al.* Trastuzumab Modulates The Protein Cargo Of Extracellular Vesicles Released By Erbb2. *Membranes* **2021**, (2021).
64. Andrade, L. N. de S. *et al.* Extracellular Vesicles Shedding Promotes Melanoma Growth in Response to Chemotherapy. *Sci Rep* **9**, 14482 (2019).
65. Keklikoglou, I. *et al.* Chemotherapy Elicits Pro-Metastatic Extracellular Vesicles In Breast Cancer Models. *Nat. Cell Biol* **21**, 190–202 (2019).
66. Bandari, S. K. *et al.* Chemotherapy Induces Secretion Of Exosomes Loaded With Heparanase That Degrades Extracellular Matrix And Impacts Tumor And Host Cell Behavior. *Matrix Biol* **65**, 104–118 (2018).
67. Thorburn, J. *et al.* Autophagy Regulates Selective Hmgb1 Release In Tumor Cells That Are Destined To Die. *Cell Death Differ* **16**, 175–183 (2009).

68. Claude-Taupin, A., Bissa, B., Jia, J., Gu, Y. & And Deretic, V. Role Of Autophagy In Il-1 $\beta$  Export And Release From Cells. *Semin. Cell Dev. Biol* **83**, 36–41 (2018).
69. Rak, J. L.(C3)icensing Of Exosomes For Rna Export. *Nat. Cell Biol* **22**, 137–139 (2020).
70. Murrow, L., Malhotra, R. & And Debnath, J. Atg12-Atg3 Interacts With Alix To Promote Basal Autophagic Flux And Late Endosome Function. *Nat. Cell Biol* **17**, 300–310 (2015).
71. Galluzzi, L. *et al.* Molecular Definitions Of Autophagy And Related Processes. *Embo J* **36**, 1811–1836 (2017).
72. Pathan, M. *et al.* Vesiclepedia 2019: A Compendium Of Rna, Proteins, Lipids And Metabolites In Extracellular Vesicles. *Nucleic Acids Res* **47**, 516–519 (2019).
73. Dutta, S., Warshall, C., Bandyopadhyay, C., Dutta, D. & And Chandran, B. Interactions Between Exosomes From Breast Cancer Cells And Primary Mammary Epithelial Cells Leads To Generation Of Reactive Oxygen Species Which Induce Dna Damage Response. in *Stabilization Of P53 And Autophagy In Epithelial Cells. Plos One* **9**:E97580 (2014). doi:10.1371/Journal.Pone.0097580.
74. Dai, E. *et al.* Autophagy-Dependent Ferroptosis Drives Tumor-Associated Macrophage Polarization Via Release And Uptake Of Oncogenic Kras Protein. *Autophagy* **16**, 2069–2083 (2020).
75. Xu, J., Camfield, R. & And Gorski, S. M. The Interplay Between Exosomes And Autophagy Partners In Crime. *J. Cell Sci* **131**, (2018).
76. Hessvik, N. P. *et al.* Pikfyve Inhibition Increases Exosome Release And Induces Secretory Autophagy. *Cell Mol. Life Sci* **73**, 4717–4737 (2016).
77. Ma, Y. *et al.* Exosomal Transfer Of Cisplatin-Induced Mir-425-3p Confers Cisplatin Resistance In Nscl Through Activating Autophagy. *Int. J. Nanomedicine* **14**, 8121–8132 (2019).
78. Cai, S. *et al.* Exosomal Mir-7 Mediates Bystander Autophagy In Lung After Focal Brain Irradiation In Mice. *Int. J. Biol. Sci* **13**, 1287–1296 (2017).
79. Han, M. *et al.* Exosome-Transmitted Mir-567 Reverses Trastuzumab Resistance By Inhibiting Atg5 In Breast Cancer. *Cell Death Dis* **11**, (2020).
80. Lebleu, V. S. & And Kalluri, R. Exosomes As A Multicomponent Biomarker Platform In Cancer. *Trends Cancer* **6**, 767–774 (2020).
81. Matsumoto, Y. *et al.* Quantification Of Plasma Exosome Is A Potential Prognostic Marker For Esophageal Squamous Cell Carcinoma. *Oncol. Rep* **36**, 2535–2543 (2016).
82. Osti, D. *et al.* Clinical Significance Of Extracellular Vesicles In Plasma From Glioblastoma Patients. *Clin. Cancer Res* **25**, 266–276 (2019).
83. Liu, Q. *et al.* Plasma Exosome Levels In Non-Small-Cell Lung Cancer: Correlation With Clinicopathological Features And Prognostic Implications. *Cancer Biomark* **22**, 267–274 (2018).
84. Hoshino, A. *et al.* Extracellular Vesicle And Particle Biomarkers Define Multiple Human Cancers. *Cell* **182**, 1044–1061 (2020).
85. Xie, Y. *et al.* Rna-Seq Profiling Of Serum Exosomal Circular Rnas Reveals Circ-Pnn As A Potential Biomarker For Human Colorectal Cancer. *Front. Oncol* **10**, (2020).
86. Bestard Escalas, J. *et al.* Fatty Acid Unsaturation Degree Of Plasma Exosomes In Colorectal Cancer Patients: A Promising Biomarker. *Int. J. Mol. Sci* **22**, (2021).
87. Xu, R. *et al.* Extracellular Vesicles In Cancer - Implications For Future Improvements In Cancer Care. *Nat. Rev. Clin. Oncol* **15**, 617–638 (2018).
88. Dai, J. *et al.* Exosomes: Key Players In Cancer And Potential Therapeutic Strategy. *Signal Transduct. Target Ther* **5**, (2020).
89. Srivastava, A. *et al.* Nanosomes Carrying Doxorubicin Exhibit Potent Anticancer Activity Against Human Lung Cancer Cells. *Sci. Rep* **6**, (2016).
90. Kim, M. S. *et al.* Development Of Exosome-Encapsulated Paclitaxel To Overcome Mdr In Cancer Cells. *Nanomedicine* **12**, 655–664 (2016).
91. Kamekar, S. *et al.* Exosomes Facilitate Therapeutic Targeting Of Oncogenic Kras In Pancreatic Cancer. *Nature* **546**, 498–503 (2017).
92. Qi, H. *et al.* Blood Exosomes Endowed With Magnetic And Targeting Properties For Cancer Therapy. *Acs Nano* **10**, 3323–3333 (2016).
93. Zhang, H., Lu, J., Liu, J., Zhang, G. & And Lu, A. Advances In The Discovery Of Exosome Inhibitors In Cancer. *J. Enzyme Inhib. Med. Chem* **35**, 1322–1330 (2020).